secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001641172-25-022908
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025
--------------------------------------------------------------------------------

- Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
- HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.
- Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.
- Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.
- No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/0001641172-25-022908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer